| Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] |
| |
|
September 30, 2024 |
|
| |
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
| Current assets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Money market funds |
|
$ |
13,889 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
13,889 |
|
| Total assets measured at fair value |
|
$ |
13,889 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
13,889 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Derivative liabilities - royalty agreement |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
1,418 |
|
|
$ |
1,418 |
|
| Convertible notes payable |
|
|
— |
|
|
|
— |
|
|
|
13,250 |
|
|
|
13,250 |
|
| Total liabilities measured at fair value |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
14,668 |
|
|
$ |
14,668 |
|
| |
|
December 31, 2023 |
|
| |
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
| Current assets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Money market funds |
|
$ |
7,203 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
7,203 |
|
| Total assets measured at fair value |
|
$ |
7,203 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
7,203 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Derivative liabilities - royalty agreement |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
1,014 |
|
|
$ |
1,014 |
|
| Total liabilities measured at fair value |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
1,014 |
|
|
$ |
1,014 |
|
|
| |
|
December 31, 2023 |
|
| |
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
| Current assets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Money market funds |
|
$ |
7,203 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
7,203 |
|
| Total assets measured at fair value |
|
$ |
7,203 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
7,203 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Derivative liabilities – royalty agreement |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
1,014 |
|
|
$ |
1,014 |
|
| Total liabilities measured at fair value |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
1,014 |
|
|
$ |
1,014 |
|
| |
|
December 31, 2022 |
|
| |
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
| Current assets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Money market funds |
|
$ |
15,203 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
15,203 |
|
| Total assets measured at fair value |
|
$ |
15,203 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
15,203 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Derivative liabilities – royalty agreement |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
1,499 |
|
|
$ |
1,499 |
|
| Total liabilities measured at fair value |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
1,499 |
|
|
$ |
1,499 |
|
|
| Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] |
| |
|
September 30, 2024 |
|
|
December 31, 2023 |
|
| Discount rate |
|
|
24.0 |
% |
|
|
25.0 |
% |
| Probability rate of achieving FDA approval of a product |
|
|
56.6 |
% |
|
|
50.0 |
% |
| Expected term to FDA regulatory approval of a product (in years) |
|
2.67 |
|
|
|
3.50 |
|
| |
|
September 30, 2024 |
|
| Risk-free interest rate |
|
|
4.40 |
% |
| Volatility |
|
|
77.50 |
% |
| Dividend yield |
|
|
0.00 |
% |
| Probability-weighted remaining term (years) |
|
|
0.5 |
|
| Stock price |
|
$ |
3.67 |
|
|
| |
|
December 31, |
|
| |
|
2023 |
|
|
2022 |
|
| Discount rate |
|
|
25.0 |
% |
|
|
25.0 |
% |
| Probability rate of achieving FDA approval of a product |
|
|
50 |
% |
|
|
50 |
% |
| Expected term to FDA regulatory approval of a product (in years) |
|
|
3.50 |
|
|
|
1.75 |
|
|
| Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] |
| |
|
Three Months Ended September 30, 2024 |
|
|
Nine Months Ended September 30, 2024 |
|
| Balance, beginning of period |
|
$ |
1,343 |
|
|
$ |
1,014 |
|
| Fair value adjustments |
|
|
75 |
|
|
|
404 |
|
| Balance, end of the period |
|
$ |
1,418 |
|
|
$ |
1,418 |
|
|
| |
|
2023 |
|
|
2022 |
|
| Derivative liabilities – royalty agreement |
|
|
|
|
|
|
|
|
| Balance at January 1 |
|
$ |
1,499 |
|
|
$ |
1,199 |
|
| Fair value adjustments on derivative liabilities |
|
|
(485 |
) |
|
|
300 |
|
| Balance at December 31 |
|
$ |
1,014 |
|
|
$ |
1,499 |
|
|